FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis ...

Discover how inflammation peptides are revolutionising our understanding of immune regulation, offering new avenues for ...

Peptides have emerged as indispensable tools in modern drug discovery, playing a central role in areas such as oncology, metabolic disorders, targeted delivery, and protein–protein interaction ...

Phase 2 topline data from Avail trial expected in Q3 2025. Topline results from the Phase 2 Avail trial of canvuparatide, a potential long-acting, once-weekly parathyroid hormone (PTH) peptide prodrug ...

Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide ...